Five-Year Extended Follow-Up Results: Dual Immunotherapy as First-line Treatment for Certain Advanced Renal Cell Carcinoma Patients

Sponsored by Bristol Myers Squibb For health care professionals (HCPs) treating patients diagnosed with renal cell carcinoma (RCC), finding an effective treatment option can be challenging.1 Historically, the prognosis for RCC patients has been poor with the most recent data (2011-2017) pointing to a five-year survival rate of 13.9% for advanced cases.2 Fortunately, research has…

Next post in Brain Cancer